Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tyvyt

- PMLiVE

FDA approves expanded indication for Gilotrif

US body gives Boehringer Ingelheim’s oral lung cancer treatment the nod

- PMLiVE

Merck drops once-weekly diabetes drug in US and EU

Says decision is due to “business reasons” not safety or efficacy issues

- PMLiVE

FDA panel says no to quick approval of Clovis’ rociletinib

Recommends waiting for phase III trial results after "serious" safety concerns

AstraZeneca AZ

AZ gets $100m from Lilly as Alzheimer’s drug progresses

BACE inhibitor candidate displays ‘encouraging’ positive safety data

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo gets two new indications in Europe

Receives green light as lung and kidney cancer immunotherapy

EU flag

Boehringer’s Giotrif wins new NSCLC licence in Europe

Can now be marketed for advanced squamous cell carcinoma of the lung

Eli Lilly HQ

Lilly wins European approval for lung cancer drug Portrazza

First biologic licenced in EU as a first-line treatment for adults with NSCLC

- PMLiVE

Pharma forms Parkinson’s disease trials consortium

Hopes to make clinical trials “smarter” through sharing of past PD trial data

Eli Lilly HQ

UK court backs Actavis in dispute over Lilly’s Alimta

Actavis’ generic version ruled not to infringe Lilly’s intellectual property

Eli Lilly HQ

Eli Lilly files oral rheumatoid arthritis drug baricitinib in US

Hopes for approval later this year after the drug outperformed Humira in trials

- PMLiVE

Xalkori set for rapid review in new lung cancer indication

Pfizer could produce first FDA-approved biomarker-driven therapy for ROS1-positive NSCLC

Eli Lilly HQ

FDA clears Lilly’s lung cancer drug Portrazza

First biologic drug to be approved as first-line therapy for NSCLC

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links